Immatics N.V.
IMTXHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. With a market capitalization of $1.37B, it sits in small-cap territory. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Market Cap
$1.37B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-5.30
EPS (TTM)
$-1.99
EPS (Fwd)
$-1.89
ROE
-43.2%
ROA
-22.4%
Cash
$453.6M
Total Debt
$15.1M
Free CF
-$111.9M
52W Change
74.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $453.6M in cash comfortably exceeding the $15.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$111.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -43.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $172.8M (2022) to $48.3M (2025), a 72% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IMTX.